Results 21 to 30 of about 20,010 (263)

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Molecular Cancer, 2011
Background Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major
Packman Kathryn, Xia Mingxuan, Kolinsky Kenneth, Higgins Brian, Tovar Christian, Heimbrook David C, Vassilev Lyubomir T   +6 more
doaj   +1 more source

Endocrine disrupting potential of selected azole and organophosphorus pesticide products through suppressing the dimerization of human androgen receptor in genomic pathway

Ecotoxicology and Environmental Safety, 2022
Several pesticides widely used in agriculture have been considered to be endocrine disrupting chemicals through their binding affinities to estrogen or androgen receptors.
Da-Woon Jung, Da-Hyun Jeong, Hee-Seok Lee   +2 more
doaj   +1 more source

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer

Cell Death and Disease, 2022
Androgen receptor (AR) plays an important role in the progression of prostate cancer and has been targeted by castration or AR-antagonists. The emergence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) is ...
Xuanrong Chen, Yi Shao, Wanqing Wei, Shimiao Zhu, Yang Li, Yutong Chen, Hanling Li, Hao Tian, Guijiang Sun, Yuanjie Niu, Zhiqun Shang   +10 more
doaj   +1 more source

Maternal allocation of androgens and antagonistic effects of yolk androgens on sons and daughters [PDF]

Behavioral Ecology, 2005
Mothers can influence the phenotype of their offspring by adjusting the quality of their eggs in relation to sex and reproductive value of the progeny. Maternal androgens in the eggs of vertebrates may mediate such adaptive early maternal effects. However, the evolution of early maternal effects mediated by egg androgens may be constrained by the ...
Saino, Nicola, Ferrari, Rafaella Poala, Romano, Maria, Martinelli, Roberta, Lacroix, André, Gil, Diego, Moller, Anders Pape   +6 more
openaire   +4 more sources

In silico and in vitro assessment of androgen receptor antagonists

Computational Biology and Chemistry, 2021
There is a growing concern for male reproductive health as studies suggest that there is a sharp increase in prostate cancer and other fertility related problems. Apart from lifestyle, pollutants are also known to negatively affect the reproductive system.
Onur Serçinoglu, Ceyhun Bereketoglu, Per-Erik Olsson, Ajay Pradhan   +3 more
openaire   +3 more sources

Androgen receptor antagonists for prostate cancer therapy [PDF]

Endocrine-Related Cancer, 2014
Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa.
Christine, Helsen, Thomas, Van den Broeck, Arnout, Voet, Stefan, Prekovic, Hendrik, Van Poppel, Steven, Joniau, Frank, Claessens   +6 more
openaire   +2 more sources

The characteristics of adverse reactions of three anti-prostate cancer drugs based on Vigiaccess database and bibliometric analysis

Frontiers in Pharmacology
BackgroundAndrogen antagonists, including apalutamide, darolutamide, and enzalutamide, play a crucial role in the treatment of prostate cancer.
Jianqing Wang, Jia You, Weixing Huang, Weixing Huang, Chiting Yuan, Jiangjie Chen, Feifei Wang, Wei Wang, Liwei Zhang, Liwei Zhang   +9 more
doaj   +1 more source

High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor

Cells, 2020
Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic disease ...
Hadjer Dellal, Abdelhay Boulahtouf, Elina Alaterre, Alice Cuenant, Marina Grimaldi, William Bourguet, Céline Gongora, Patrick Balaguer, Philippe Pourquier   +8 more
doaj   +1 more source

Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.

PLoS ONE, 2013
The management of hormone-refractory prostate cancer represents a major challenge in the therapy of this tumor, and identification of novel androgen receptor antagonists is needed to render treatment more effective.
Anna Tesei, Carlo Leonetti, Marzia Di Donato, Elisa Gabucci, Manuela Porru, Greta Varchi, Andrea Guerrini, Dino Amadori, Chiara Arienti, Sara Pignatta, Giulia Paganelli, Michele Caraglia, Gabriella Castoria, Wainer Zoli   +13 more
doaj   +1 more source

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer [version 4; peer review: 2 approved]

F1000Research
Background: Prostate cancer is a disease that occurs in men aged more than 50 years. In Iraq, 8.89 men per 100,000 population suffer from prostate cancer, with the incidence being 14,016 cases and mortality being 6,367 cases.
Hany Akeel Al-Hussaniy, Mohammed J. AL-Zobaidy, Zahraa S. Al-tameemi   +2 more
doaj   +1 more source